Skip to main content
MedPathMedPath Home
Clinical Trials/NCT05653765
NCT05653765
Active, not recruiting
Not Applicable

Prognostic Value of the Angio-based Microvascular Resistance Use One Single Angiographic View Measured After Primary Percutaneous Coronary Intervention in ST-segment Elevation Myocardial Infarction Patients

Henan Institute of Cardiovascular Epidemiology5 sites in 1 country2,663 target enrollmentDecember 20, 2022
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsCoronary Heart DiseaseST Elevation Myocardial Infarction

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Coronary Heart Disease
Sponsor
Henan Institute of Cardiovascular Epidemiology
Enrollment
2663
Locations
5
Primary Endpoint
MACEs
Status
Active, not recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

The goal of this observational study is to learn about in STEMI with Primary PCI Patients. The main questions it aims to answer are:

  • To determine the value of AMR in predicting the long-term clinical prognosis of patients with STEMI after PPCI, and to find the best cut-off value.
  • Analyze the factors of PPCI affecting AMR and explore the effective measures of PPCI microcirculation protection.

Radiographic images of STEMI receiving primary PCI treatment in several chest pain centers in China will be included. The last image of the infarct-related vessel will be used as a target to calculate its AMR. The relationship between AMR and long-term clinical prognosis was analyzed.

Registry
clinicaltrials.gov
Start Date
December 20, 2022
End Date
March 20, 2025
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Henan Institute of Cardiovascular Epidemiology
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •Aged 18 or older
  • •Type 1 myocardial infarction
  • •Receive PPCI

Exclusion Criteria

  • •Failed to identify culprit vessels.
  • •Structural heart disease with moderate to severe aortic valve or mitral regurgitation and or stenosis that may affect cardiac function
  • •Dialysis patients with severe renal insufficiency
  • •Severe and uncontrollable arrhythmia
  • •Complicated with dilated cardiomyopathy
  • •Unable to tolerate dual antiplatelet therapy
  • •Severe and uncontrollable anemia
  • •Hyperthyroidism
  • •TIMI blood flow 0-1 grade after PPCI

Outcomes

Primary Outcomes

MACEs

Time Frame: 12 months

cardiac death, hospitalization for heart failure, target vessel revascularization，non-fatal MI

Secondary Outcomes

  • cardiac death(12 months)
  • hospitalization for heart failure(12 months)
  • target lesion revascularization(12 months)
  • Repeated myocardial infarction(12 months)

Study Sites (5)

Loading locations...

Similar Trials

Completed
Phase 3
Minimal Invasive Procedure for Myocardial InfarctionST Elevation Myocardial Infarction
NCT01360242Centre Hospitalier Annecy Genevois160
Recruiting
Not Applicable
Physiologic Assessment of Microvascular Function in Heart Transplant PatientsCardiac Allograft Vasculopathy
NCT02798731Samsung Medical Center200
Recruiting
Not Applicable
Coronary Microvascular Dysfunction in Angina Patients With Non-obstructive Coronary Artery Disease (ANOCA-CMD)Angina Patients With Non-obstructive Coronary Artery DiseaseCoronary Microvascular DysfunctionIndex of Microvascular Resistance
NCT06503640China-Japan Friendship Hospital100
Unknown
Not Applicable
Diagnostic and Prognostic Value of Angiography-derived IMRCoronary Microvascular DysfunctionMyocardial Ischemia
NCT04825028Shanghai Zhongshan Hospital271
Completed
Not Applicable
Investigating the Utility of Remote Index of Microvascular Resistance in Patients With Chronic Total OcclusionChronic Total Occlusion
NCT04226326University of Chicago4